S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
pixel
Log in
NASDAQ:PRAH

PRA Health Sciences Stock Forecast, Price & News

$142.81
-1.52 (-1.05 %)
(As of 03/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$142.70
Now: $142.81
$145.95
50-Day Range
$120.83
MA: $129.85
$151.66
52-Week Range
$58.67
Now: $142.81
$155.00
Volume1.99 million shs
Average Volume622,539 shs
Market Capitalization$9.22 billion
P/E Ratio41.76
Dividend YieldN/A
Beta1.24
PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company has a partnership with The Leukemia & Lymphoma Society to launch a clinical trial for developing treatments for children with relapsed acute leukemia. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.
PRA Health Sciences logo

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRAH
CUSIPN/A
Phone919-786-8200
Employees17,500
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.07 billion
Cash Flow$7.65 per share
Book Value$17.23 per share

Profitability

Net Income$243.02 million

Miscellaneous

Market Cap$9.22 billion
Next Earnings Date4/29/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.46 out of 5 stars

Medical Sector

506th out of 1,969 stocks

Commercial Physical Research Industry

10th out of 42 stocks

Analyst Opinion: 1.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
$142.81
-1.52 (-1.05 %)
(As of 03/2/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PRAH News and Ratings via Email

Sign-up to receive the latest news and ratings for PRAH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











PRA Health Sciences (NASDAQ:PRAH) Frequently Asked Questions

Is PRA Health Sciences a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PRA Health Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRAH, but not buy additional shares or sell existing shares.
View analyst ratings for PRA Health Sciences
or view top-rated stocks.

What stocks does MarketBeat like better than PRA Health Sciences?

Wall Street analysts have given PRA Health Sciences a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but PRA Health Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting PRA Health Sciences?

PRA Health Sciences saw a decline in short interest in January. As of January 15th, there was short interest totaling 747,200 shares, a decline of 23.2% from the December 31st total of 972,700 shares. Based on an average trading volume of 269,000 shares, the short-interest ratio is currently 2.8 days. Currently, 1.2% of the shares of the company are sold short.
View PRA Health Sciences' Short Interest
.

When is PRA Health Sciences' next earnings date?

PRA Health Sciences is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for PRA Health Sciences
.

How were PRA Health Sciences' earnings last quarter?

PRA Health Sciences, Inc. (NASDAQ:PRAH) released its earnings results on Wednesday, February, 24th. The medical research company reported $1.55 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.24 by $0.31. PRA Health Sciences had a trailing twelve-month return on equity of 22.21% and a net margin of 7.09%.
View PRA Health Sciences' earnings history
.

How has PRA Health Sciences' stock been impacted by Coronavirus?

PRA Health Sciences' stock was trading at $88.68 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PRAH stock has increased by 61.0% and is now trading at $142.81.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for PRAH?

11 brokers have issued twelve-month price objectives for PRA Health Sciences' shares. Their forecasts range from $89.00 to $145.00. On average, they anticipate PRA Health Sciences' share price to reach $110.20 in the next twelve months. This suggests that the stock has a possible downside of 22.8%.
View analysts' price targets for PRA Health Sciences
or view top-rated stocks among Wall Street analysts.

Who are PRA Health Sciences' key executives?

PRA Health Sciences' management team includes the following people:
  • Mr. Colin Shannon, Chairman, CEO & Pres (Age 62, Pay $1.04M)
  • Mr. Michael J. Bonello, Exec. VP & CFO (Age 51, Pay $480.54k)
  • Mr. Kent Thoelke, Exec. VP & Chief Scientific Officer
  • Mr. Christopher L. Gaenzle, Exec. VP, Chief Admin. Officer, Gen. Counsel & Corp. Sec. (Age 54)
  • Mr. Thomas Byrne, VP of Legal Affairs
  • Laurie Hurst, Sr. Director of Communications & PR
  • Ms. Tami Klerr-Naivar, Exec. VP and Chief Sales & Marketing Officer
  • Mr. Patrick R. Spine, VP of HR (Age 50)
  • Dr. Michael Kirchengast, Sr. VP of Scientific Affairs
  • Mr. David G. Passov, Sr. VP & Head of Project Management - EAPA

What is Colin Shannon's approval rating as PRA Health Sciences' CEO?

500 employees have rated PRA Health Sciences CEO Colin Shannon on Glassdoor.com. Colin Shannon has an approval rating of 87% among PRA Health Sciences' employees.

Who are some of PRA Health Sciences' key competitors?

What other stocks do shareholders of PRA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Adobe (ADBE), Applied Materials (AMAT), Abbott Laboratories (ABT), The Walt Disney (DIS), PayPal (PYPL), Veeva Systems (VEEV), Pfizer (PFE) and AbbVie (ABBV).

When did PRA Health Sciences IPO?

(PRAH) raised $306 million in an initial public offering (IPO) on Thursday, November 13th 2014. The company issued 17,000,000 shares at $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

What is PRA Health Sciences' stock symbol?

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

Who are PRA Health Sciences' major shareholders?

PRA Health Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (11.00%), BlackRock Inc. (10.01%), Janus Henderson Group PLC (3.74%), NN Investment Partners Holdings N.V. (2.19%), Pendal Group Limited (1.61%) and Bank of New York Mellon Corp (1.02%). Company insiders that own PRA Health Sciences stock include Christopher L Gaenzle, Colin Shannon, Fund Holdings LP Kkr and Michael J Bonello.
View institutional ownership trends for PRA Health Sciences
.

Which institutional investors are selling PRA Health Sciences stock?

PRAH stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Vaughan Nelson Investment Management L.P., Tygh Capital Management Inc., Price T Rowe Associates Inc. MD, Squarepoint Ops LLC, Bank of New York Mellon Corp, Wells Fargo & Company MN, and Epoch Investment Partners Inc.. Company insiders that have sold PRA Health Sciences company stock in the last year include Christopher L Gaenzle, Colin Shannon, and Michael J Bonello.
View insider buying and selling activity for PRA Health Sciences
or view top insider-selling stocks.

Which institutional investors are buying PRA Health Sciences stock?

PRAH stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Peregrine Capital Management LLC, Nuveen Asset Management LLC, Assenagon Asset Management S.A., Captrust Financial Advisors, Barclays PLC, BlackRock Inc., and JPMorgan Chase & Co..
View insider buying and selling activity for PRA Health Sciences
or or view top insider-buying stocks.

How do I buy shares of PRA Health Sciences?

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PRA Health Sciences' stock price today?

One share of PRAH stock can currently be purchased for approximately $142.81.

How much money does PRA Health Sciences make?

PRA Health Sciences has a market capitalization of $9.22 billion and generates $3.07 billion in revenue each year. The medical research company earns $243.02 million in net income (profit) each year or $4.80 on an earnings per share basis.

How many employees does PRA Health Sciences have?

PRA Health Sciences employs 17,500 workers across the globe.

What is PRA Health Sciences' official website?

The official website for PRA Health Sciences is www.prahs.com.

Where are PRA Health Sciences' headquarters?

PRA Health Sciences is headquartered at 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612.

How can I contact PRA Health Sciences?

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]


This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.